Advanced Cell to Host Investor Conference Call to Discuss Breakthrough Technique to Generate Embryonic Stem Cells without Harming Embryo; Proprietary Method May Remove Ethical and Political Obstacles to Stem Cell Research and Federal Funding.

ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB:ACTC), developers of groundbreaking human embryonic stem cell technologies to create next-generation medical therapies, will hold an investor conference call on Friday, August 25, 2006, at 12 noon Eastern, to discuss its novel technique to generate human embryonic stem cell lines from embryos while fully preserving the embryo's potential for life and development.

The proprietary technique, which was recently published in the scientific journal "Nature," aims to resolve many of the ethical issues currently stunting embryonic stem cell research and may finally open the door to needed funding from the federal government.

During the conference call, William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology (ACT), and Dr. Michael D. West, Ph.D., President and Chief Scientific Officer of ACT, will discuss the company's scientific advances and business initiatives, and will address investor questions.

Among the primary ethical objections of those who oppose the generation of human embryonic stem cells is that all techniques, until now, have resulted in the destruction of the embryo. The company's newly published proprietary technique may overcome this hurdle, offering the potential to speed the progress of stem cell science from laboratory to bedside.

"We hope that this new technique will allow us to make stem cell lines widely available for researchers around the country," said Mr. Caldwell. "Our goal is to help accelerate basic research and enable the translation of that research into real cures and treatments for many of the world's most devastating diseases."

In the paper in "Nature," ACT scientists described their technique to generate human embryonic stem cells (hES cells) using a method for deriving stem cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). PGD is a widely used practice used at in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos. To date, more than 1,500 healthy children have been born following the procedure, and live with their families today.

Current embryonic stem cell technology is the source of a heated national controversy because it derives hES cells from the inner cell mass of later-stage embryos known as blastocysts, destroying their potential for further development. "What has made ACT's novel approach so groundbreaking is its ability to generate stem cell lines of equal scientific value from a single cell obtained from an 8-cell-stage embryo, while maintaining the embryo's potential to develop normally," said Mr. Caldwell.

Callers within the United States can access the conference call by calling [phone], when prompted tell the operator you would like to connect to the 'Advanced Cell Technology conference call.' International callers can dial [phone]. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell/.

About Advanced Cell Technology, Inc.

Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.